Home
Company
Drug Development
Technology
Partnering
Investors
Imprint

Welcome to conoGenetix biosciences GmbH!

conoGenetix - located in the heart of the Biotech-Cluster Martinsried - is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of autoimmune diseases.

conoGenetix was founded in 2002 by Dr. Andreas Klostermann and Dr. Jörg Stockhaus. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets causatively involved in the generation of autoimmune diseases. conoGenetix runs a program targeting severe autoimmune disorders like Vasculitis, Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA) having several drug candidates in preclinical development.


N E W S

 

23/01/2013 - conoGenetix receives bavarian BayBio-Grant  

Martinsried, January 2013 - Today conoGenetix biosciences GmbH announced the receipt of the bavarian BayBio-Grant to intensify the development of its plattform technology for the identification of ion channel active peptides for therapeutic intervention.

 

 

16/07/2012 - conoGenetix receives BMBF Grant under the Leading Edge Cluster Program „m4 – Personalized Medicine and Targeted Therapies“

Martinsried, July 2012 – conoGenetix biosciences GmbH announces the receipt of a 1.4 Mio. Euro BMBF grant within the m4 - Personalized Medicine and Targeted Therapies Cluster to drive the development of the company`s proprietary compounds in the field of autoimmune diseases. conoGenetix aims to identify and develop small peptide therapeutics as ion channel antagonists in certain autoimmune diseases such as Vasculitis and Rheumatoid Arthritis.

“The BMBF funding of our R&D project in this indication area is a further validation of our approach in targeting T-cell mediated autoimmune diseases with small and selective peptides,” said Dr. Andreas Klostermann, CEO.

About conoGenetix biosciences GmbH - conoGenetix is a privately owned biopharmaceutical company focused on the development of new ion channel selective peptides. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets - e.g. causatively involved in the generation of autoimmune diseases. Currently, conoGenetix runs a program targeting severe autoimmune disorders like Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Vasculitis. Several peptides called cgtx-peptides within this program are in preclinical development. The leading indication for the cgtx-peptides is Vasculitis – a fatal disease strongly related to Rheumatoid Arthritis. Vasculitis is a rare disease and will be a market door opener for conoGenetix. A successful entry into phase I/IIa clinical trials at the end of this financing round will raise the valuation of the company significantly.

About the “m4 – Personalized Medicine and Targeted Therapies Cluster“ - The Leading-Edge Cluster Competition was launched in 2007 within the scope of the high-tech strategy of the German Federal Government. In 2010 the Munich Biotech Cluster was awarded as one of the Leading Edge Clusters in Germany. Within a period of 5 years, the Cluster is funded with EUR 40 milion by the BMBF. The funding is supplemented by more than EUR 40 milion by the participating companies in about 40 R&D projects. For more information please visit: www.m4.de

 

 

18/04/2012 - conoGenetix announces Series A financing round

Martinsried, April 2012 - Today conoGenetix biosciences GmbH announced the closing of a Series A financing round with a volume of more than 1.5 million Euro. Lead Investor is Mey Capital Matrix GmbH, a family-office like Venture Capital Company. The existing investor BioM AG also participated in the round.

"The financing round is an important milestone for us and will enable us to develop our proprietary pipeline of anti-inflammatory peptides and to progress one of our drug candidates into clinical trials." said Dr. Andreas Klostermann, CEO of conoGenetix. Prof. Dr. Domdey, CEO of BioM AG, emphasized the high innovative potential of conoGenetix.  

 

18/04/2012 - conoGenetix gibt Abschluß einer Serie A Finanzierung bekannt

Die conoGenetix biosciences GmbH gab heute den Abschluss einer kürzlich erfolgten Serie A Finanzierungsrunde mit einem Volumen von mehr als 1.5 Mio. Euro bekannt. Als Lead-Investor konnte die Mey Capital Matrix GmbH, eine Family Office geprägte Beteiligungsgesellschaft aus der Region München, gewonnen werden. Weiterhin beteiligte sich die BioM AG, Martinsried, die das Unternehmen bereits über ein Seed-Investment finanziert hatte, an dieser Finanzierungsrunde.

„Mit diesem Investment wird die conoGenetix bioscienes GmbH in die Lage versetzt, ihre innovativen Peptid-Compounds für den Indikationsbereich der Autoimmunerkrankungen bis zur klinischen Erprobung zu entwickeln.“ – zeigte sich Geschäftsführer Dr. Andreas Klostermann zuversichtlich. Prof. Dr. Domdey, Vorstand der BioM AG, zeigte sich ebenfalls hoch erfreut über den Abschluss der Finanzierungsrunde und betonte die hohe Innovationskraft des Unternehmens.

 

conoGenetix biosciences GmbH